The noncoding function of NELFA mRNA promotes the development of oesophageal squamous cell carcinoma by regulating the Rad17-RFC2-5 complex

Jiancheng Xu1, Guangchao Wang1, Wei Gong1, Shichao Guo1, Dan Li1 and Qimin Zhan1,2

1 State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Laboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Keywords
ESCC; NELFA mRNA; Rad17; RFC2-5; USF2

Correspondence
Q. Zhan, State Key Laboratory of Molecular Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Clinical Research Center, National Cancer Center, Beijing 100021, China
Tel: +86 010 87787496
E-mail: zhanqimin@bjmu.edu.cn

(Rceived 24 August 2019, revised 27 November 2019, accepted 13 December 2019, available online 28 January 2020)
doi:10.1002/1878-0261.12619

Recently, RNAs interacting with proteins have been implicated in playing an important role in the occurrence and progression of oesophageal squamous cell carcinoma (ESCC). In this study, we found that NELFA mRNA interacts with Rad17 through a novel noncoding mode in the nucleus and that the aberrant expression of USF2 contributed to the upregulation of Rad17 and NELFA. Subsequent experiments demonstrated that the deletion of NELFA mRNA significantly decreased ESCC proliferation and colony formation in vitro. Moreover, NELFA mRNA knockdown inhibited DNA damage repair and promoted apoptosis. Mechanistic studies indicated that NELFA mRNA regulated the interaction between Rad17 and RFC2-5, which had a major impact on the phosphorylation of CHK1, CHK2 and BRCA1. NELFA mRNA expression was consistently elevated in ESCC patients and closely related to decreased overall survival. Taken together, our results confirmed the critical role of the noncoding function of NELFA mRNA in ESCC tumorigenesis and indicated that NELFA mRNA can be regarded as a therapeutic target and an independent prognostic indicator in ESCC patients.

1. Introduction

Oesophageal cancer accounts for one of the leading causes of cancer-related deaths worldwide (Alsop and Sharma, 2016). Approximately 70% of oesophageal cancer patients in the world are Chinese, of which over 90% have ESCC (Domper Arnal et al., 2015; Huang and Yu, 2018). Despite recent technological advancements in early diagnosis and treatment, the 5-year survival rate of patients is still poor (Masuike et al., 2018; Yoshimizu et al., 2018). At present, the specific mechanisms of oesophageal cancer onset and progression remain to be further defined. Above all, it is essential to investigate the molecular mechanisms involved in ESCC development and progression, thus facilitating new treatment strategies for ESCC patients.

Human Rad17, homologous to Schizosaccharomyces pombe rad17, plays an important role in DNA damage repair by forming a protein complex with RFC2-5, which is vital for cell survival under genotoxic stress (Bao et al., 1999; Bao et al., 1998; Griffith et al., 2002). Rad17 is essential for cell growth and chromosomal integrity and has weak ATPase activity required for binding to chromatin (Lindsay-Boltz et al., 2001). The Rad17-RFC2-5 complex participates in the ATR/ATM-mediated phosphorylation of genes

Abbreviations
ASO, antisense oligonucleotide; CoIP, co-immunoprecipitation; DSB, DNA double-strand break; EdU, 5-ethynyl-2′-deoxyuridine; EMSA, electrophoretic mobility shift assay; ENCODE, encyclopedia of DNA elements; ESCC, oesophageal squamous cell carcinoma; FCM, flow cytometry; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GEPIA, gene expression profiling interactive analysis; IR, ionizing radiation; IncRNAs, long noncoding RNAs; qRT-PCR, quantitative real-time polymerase chain reaction; RACE, rapid amplification of cDNA ends; RIP, RNA immunoprecipitation; RPISeq, RNA–protein interaction prediction; SD, standard deviation; TCGA, The Cancer Genome Atlas.
located downstream of the DNA damage response (Bao et al., 2001; Medhurst et al., 2008). In addition, the Rad17-RFC2-5 complex, as a loader complex, facilitates Rad9-Hus1-Rad1 loading onto chromatin (Hirai and Wang, 2002; Takeishi et al., 2015). In this process, the phosphorylation of Rad17 at Ser 635 and Ser 645 is essential for the interaction between the Rad17-RFC2-5 complex and Rad9-Hus1-Rad1 (Bao et al., 2001; Bermudez et al., 2003; Medhurst et al., 2008; Zou et al., 2002). Previous studies have reported that human Rad17 is overexpressed in diverse cancers, including colon carcinoma, breast cancer, pancreatic cancer, gastric cancer and non-small-cell lung cancer (Bao et al., 1999; Fredebohm et al., 2013; Sasaki et al., 2001; Zhou et al., 2013). The human protein NELFA, a component of the NELF complex, negatively regulates RNA polymerase II transcription elongation and is highly expressed in fetal tissues compared to adult tissues (Bastide et al., 2016). Previous studies have shown that NELFA is involved in the transcription initiation and translation elongation of HIV (Natarajan et al., 2013; Pagano et al., 2014; Ping and Rana, 2001). Furthermore, NELFA is associated with the phenotype of Wolf–Hirschhorn syndrome (Kerzendorfer et al., 2012). Until now, there has been no research on the correlation between NELFA and ESCC.

In our study, we found that a noncoding function of NELFA mRNA facilitated ESCC growth by interacting with Rad17. In addition, we confirmed that the expression of NELFA mRNA and Rad17 was higher in ESCC cells than in immortalized oesophageal epithelium cells, which was partially resulted from overexpression of the transcription factor USF2. Moreover, NELFA mRNA knockdown with unchanged NELFA protein expression levels achieved significantly inhibited ESCC cell proliferation, colony formation and DNA damage repair and promoted ESCC cell apoptosis in vitro. Further mechanistic investigations indicated that NELFA mRNA exerted a noncoding function on DNA damage repair by regulating the interaction between Rad17 and RFC3/4. Most importantly, we demonstrated that the high expression level of NELFA mRNA was closely related to poor patient survival and might be viewed as an independent prognostic indicator for oesophageal cancer patients.

2. Materials and methods

2.1. Cell lines

The human ESCC cell lines KYSE30 and KYSE180 were obtained from Y. Shimada of Kyoto University. KYSE30 and KYSE180 cells were cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific, Carlsbad, CA, USA) supplemented with 10% FBS. The immortalized oesophageal epithelium cell line NE3 was cultured in a 1:1 mixture of Epilife and defined keratinocyte serum-free medium (all from Gibco). All cell lines were grown at 37 °C in humidified air with 5% CO2. The source of all cell lines have been recently authenticated and tested for mycoplasma contamination, and no cross-contaminated cell lines and mycoplasma contamination were found.

2.2. RNA immunoprecipitation assay

RNA immunoprecipitation (RIP) was carried out using an EZ Magna RIP Kit (Millipore, Bedford, MA, USA) according to the manufacturer’s instructions. Briefly, KYSE30 and KYSE180 cells were lysed with RIP lysis buffer, and the supernatants were transferred to another tube for use. Fifty microlitres of protein A/G magnetic beads were incubated with anti-Rad17 at room temperature for 30 min and then washed twice. The above supernatants were immunoprecipitated with beads/anti-Rad17 complex in 900 µL of RIP Immunoprecipitation Buffer at 4 °C overnight. Finally, the immunoprecipitated RNA was detected by RT-PCR.

2.3. RNA pull-down

First, biotinylated RNA was transcribed by a MEG script™ T7 Transcription Kit (Invitrogen, Carlsbad, CA, USA) in vitro. Fifty picomoles of biotinylated RNA was heated at 95 °C for 2 min in an RNA structure buffer (10 mM Tris/HCl pH 7.0, 10 mM MgCl2, 0.1 M KCl) and then cooled down at a rate of 1 °C per minute, during which the RNA secondary structure was restored. Subsequently, folded RNA was mixed with cell extracts in binding buffer and incubated for 30 min at room temperature. Fifty microlitres of blocked streptavidin agarose beads (GE, Marlborough, MA, USA) was added into each reaction and incubated for 15 min at room temperature. Finally, the beads were boiled in 2× SDS loading buffer, and the supernatants were detected by western blot analysis.

2.4. Rapid amplification of cDNA ends

A SMARTer® rapid amplification of cDNA ends (RACE) 5'/3' Kit was used to clone the 5'/3' cDNA ends of NELFA (Clontech, Kusatsu, Shiga, Japan). A QIAquick® Gel Extraction Kit was used to purify PCR-amplified DNA fragments after agarose gel electrophoresis (Qiagen, Valencia, CA, USA). Purified
DNA fragments were cloned into the pRACE vector (Clontech), and the 5'/3' DNA of the NELFA sequence was identified by Sanger sequencing.

2.5. ChIP

ChIP was performed according to the manual of the ChIP Kit (CST, Boston, MA, USA). Briefly, KYSE30 and KYSE180 cells were cross-linked with 1% formaldehyde for 10 min and terminated with the addition of 0.125 M glycine solution. DNA was fragmented into pieces ranging from 150 to 900 bp by ultrasonication. Then, 15 µg of DNA fragments was immunoprecipitated with an anti-USF2 antibody or a normal rabbit IgG antibody. Immunoprecipitated DNA was purified and analysed by quantitative real-time PCR (qRT-PCR). The primers used for ChIP are listed in Table S1. Information on the antibodies is described in Table S2.

2.6. Electrophoretic mobility shift assay

Biotin-labelled probes were synthesized by Invitrogen. Electrophoretic mobility shift assay (EMSA) was performed with a Gelshift™ (Active Motif, Carlsbad, CA, USA) Chemiluminescent EMSA Kit according to the manufacturer’s suggestions. The probes used for EMSA are listed in Table S1.

2.7. Co-immunoprecipitation

Equal numbers of cells were dissolved in Pierce™ IP lysis buffer (Thermo Scientific™) for 15 min on ice, followed by centrifugation for 15 min at 16 000 g. Two micrograms of antibodies was added to each experiment and incubated overnight at 4 ºC. Fifty microlitres of protein A/G sepharose beads was added to each experiment and incubated for 2 h at 4 ºC. A subsequent immunoblot assay was used to authenticate the immunoprecipitates.

2.8. RNA in situ hybridization assay

RNA in situ hybridization (ISH) probes targeting NELFA mRNA were designed and synthesized by Advanced Cell Diagnostics (Newark, CA, USA). The expression of NELFA mRNA was detected by using an RNAscope® 2.5 HD Assay—Brown (Advanced Cell Diagnostics) according to the manufacturer’s instructions.

2.9. Small interfering RNA and ASO transfection

Aliquots of 1 x 106 cells were seeded into 60-mm dishes and incubated in humidified air with 5% CO2 at 37 ºC. Twenty-four hours later, the small interfering RNA (siRNA; 50 µM), ASO (50 µM) and negative control (50 µM) were separately transfected into cells with Lipoctamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. Knockdown efficiency was determined by qRT-PCR or western blot analysis. Detailed sequence information is listed in Table S3.

2.10. qRT-PCR

Total RNA was extracted using TRizol reagent and then subjected to reverse transcription with Trans-Script First-Strand cDNA Synthesis SuperMix (Trans-Gen Biotech, Beijing, China). Quantitative PCR was performed utilizing TB Green™ Premix Ex Taq™ II (TaKaRa, Dalian, China), and relative gene expression was determined on an ABI PRISM 7900HT Sequence Detection System. The relative expression levels of the target genes were determined based on the \(2^{-\Delta\Delta Ct} \) formula, and the human β-actin transcript level was regarded as an internal control. Information on the primers is described in Table S1.

2.11. Western blot analysis

Cells were lysed in 1x RIPA buffer containing protease inhibitor. The cell lysate was separated by SDS/PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. After blocking the PVDF membranes with Tris-buffered saline containing Tween-20 (TBST) containing 5% milk for 1 h at room temperature, the membranes were incubated with primary antibodies at 4 ºC overnight. Then, the membranes were washed with TBST three times before incubation with secondary antibodies for 1 h at room temperature. Finally, membrane chemiluminescence was detected on an ImageQuant LAS 4000 (GE). Information on the antibodies is described in Table S2.

2.12. Colony formation assay

A total of 10^3 KYSE30 and KYSE180 cells transfected with the ASO were seeded into a six-well plate. After 12 days, colonies were stained with 0.5% crystal violet and imaged.

2.13. Cell proliferation assay

A total of 2 x 10^3 KYSE30 and KYSE180 cells transfected with the ASO were seeded into a 96-well E-Plate, and the xCELLigence Real-Time Cell Analyzer (RTCA)-MP System (ACEA, Agilent Technologies, Molecular Oncology 14 (2020) 611–624 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. 613
Inc., Santa Clara, CA, USA) was used to monitor cell proliferation.

2.14. Ethynyl deoxy uridine incorporation assay
A total of $2 \times 10^5$ KYSE30 and KYSE180 cells were seeded into 96-well plates 24 h prior to transfection with the ASO. After transfection for 48 h, 5-ethynyl-2'-deoxyuridine (EdU) labelling was performed according to the manufacturer's instructions provided in the Cell-Light EdU Apollo567 In Vitro Kit (RiboBio, Guangzhou, China).

2.15. γH2AX immunofluorescent staining
A total of $2 \times 10^5$ KYSE30 and KYSE180 cells were seeded into 96-well plates 24 h prior to transfection with the ASO. After transfection for 48 h, KYSE30 and KYSE180 cells were treated with 15 Gy ionizing radiation (IR). After 3 h, γH2AX immunofluorescent staining was performed according to the manufacturer's instructions provided in the OxiSelect™ DNA Double-Strand Break (DSB) Staining Kit (CELL BIO-LABS, INC, San Diego, CA, USA).

2.16. Cell apoptosis assay
A total of $3 \times 10^5$ KYSE30 and KYSE180 cells were seeded into six-well plates 24 h prior to transfection with the ASO. After transfection for 48 h, KYSE30 and KYSE180 cells were treated with 15 Gy IR. After 3 h, KYSE30 and KYSE180 cells were stained with propidium iodide and annexin V (BD Biosciences, San Jose, CA, USA). Flow cytometry (FCM) was used to determine the percentage of apoptotic cells.

2.17. Statistical analysis
SPSS 18.0 (SPSS, IBM, Armonk, NY, USA) and GraphPad PRISM 5 (GraphPad Software Inc, LaJolla, CA, USA) software were used for statistical analyses. Student’s t-test was used to analyse differences in gene expression and the correlation between NELFA mRNA expression and clinicopathological characteristics. Univariate and multivariate Cox proportional hazards regression methods were used to analyse potential prognostic factors. The Kaplan–Meier method and the log-rank test were applied to estimate overall survival. Each P value was two-sided, and P < 0.05 was considered statistically significant. All experiments were performed in at least three independent replicates, and the data are presented as the mean ± standard deviation (SD).

3. Results

3.1. Rad17 interacts with NELFA mRNA in ESCC cells
Little is known about the potential interaction between DNA damage checkpoints and long noncoding RNAs (lncRNAs). In our research, Rad17-enriched RNAs in ESCC cells were extracted by RIP with anti-Rad17 and then analysed by high-throughput sequencing. We discovered 355 lncRNAs and 399 mRNAs that combined with Rad17. Then, RIP-qPCR was used to identify these deep sequencing data to ascertain which RNAs could directly bind to Rad17. As indicated in Fig. 1A, NELFA mRNA was highly enriched by the Rad17 antibody in ESCC cells.

In addition, the 5’ and 3’ end sequences of NELFA mRNA were cloned by RACE, and the overlapping regions of these two sequences were identical (Fig. 1B). Subsequent sequence alignment indicated that the cloned sequences were consistent with NCBI reference sequences NM_005663.4. As shown in Fig. 1C, the RNA pull-down assay proved that Rad17 could directly combine with NELFA mRNA. Additionally, the RNA–protein interaction prediction instrument RPISeq showed that Rad17 and NELFA mRNA likely interact with each other, with an RF or SVW score > 0.5 (Muppirala et al., 2011). Furthermore, we constructed different truncations of NELFA mRNA based on RPISeq prediction. The specific truncation of NELFA mRNA that mainly interacted with Rad17 was a 1681–2467 bp truncation (containing the 3’ nontranslated region and the partial ORF region), as determined by RNA pull-down assays (Fig. 1D). In summary, the above results suggest that NELFA mRNA interacts with Rad17 in ESCC cells.

3.2. Transcription factor USF2 regulates the expression of Rad17 and NELFA
As depicted in Fig. 2A, the mRNA expression levels of Rad17 and NELFA were significantly higher in ESCC cells than in NE3 cells. In addition, the protein level of Rad17 was obviously higher in ESCC cells than in NE3 cells. Interestingly, the protein level of NELFA in ESCC cells was comparable to that in NE3 cells.

To identify the potential regulators of Rad17 and NELFA overexpression in ESCC, we utilized the Encyclopedia of DNA Elements (ENCODE) database to select possible transcription factors that could bind to the promoters of Rad17 and NELFA (Davis et al.,
We found that USF2 might be the upstream regulator of Rad17 and NELFA (Fig. S1A). The Cancer Genome Atlas (TCGA) data suggested that USF2 exhibited copy number amplification. RT-qPCR and western blot results also indicated that USF2 was upregulated in ESCC cells (Fig. S1B and Fig. 2B). Furthermore, through gene expression profiling interactive analysis (GEPIA), we found that the gene expression of USF2 was positively related to RAD17 or NELFA in multiple tumours (Fig. 2C) (Tang et al., 2017). Next, we analysed the Rad17 and NELFA promoter regions and discovered that Rad17 contains two USF2-binding motifs (R1 and R2), while NELFA contains three (N1, N2 and N3) upstream of its transcriptional start sites (Fig. 2D). ChIP-qPCR assays further demonstrated that the R2 site of the Rad17 promoter and the N1 site of the NELFA promoter served as the binding site of USF2 (Fig. 2E).

The above results were further confirmed by an EMSA, as shown in Fig. 2F. We then knocked down USF2 in KYSE30 and KYSE180 cells, and Rad17 and NELFA expression was decreased (Fig. 2G). In conclusion, these results demonstrate that USF2 serves as an upstream regulator of Rad17 and NELFA overexpression in ESCC cells.

3.3. NELFA mRNA affects the proliferation of ESCC cells

Rad17 is mainly located in the cell nucleus and plays an important role in DNA damage repair. Therefore, the distribution of NELFA mRNA in cells was investigated. RNAs extracted from the nuclear and cytoplasmic fractions were subjected to RT-qPCR to identify NELFA mRNA distribution independently. NELFA mRNA was expressed in the cytoplasm and in the nucleus (Fig. 3A). Then, we used two different ASOs, ASO-2 and ASO-3, to specifically downregulate NELFA mRNA expression in the cell nucleus with no impact on the expression level of NELFA protein (Fig. 3B). Thereafter, we performed an RTCA assay. NELFA mRNA knockdown in the cell nucleus inhibited the proliferation of KYSE30 and KYSE180 cells (Fig. 3C). Likewise, clone formation assays indicated that the clone formation ability of KYSE30 and KYSE180 cells decreased dramatically when nuclear
NELFA mRNA was downregulated (Fig. 3D). Taken together, these results show that NELFA mRNA regulates ESCC cell growth.

3.4. NELFA mRNA affects DNA damage repair and the apoptosis of ESCC cells

Previous studies have shown that the major function of Rad17 is in DNA damage repair. However, whether NELFA mRNA interacts with Rad17 and participates in DNA damage repair remains unknown. To elucidate the impact of NELFA mRNA on DNA damage repair, we constructed a DNA damage repair model induced with IR. Then, we detected γH2AX immunofluorescence in KYSE30 and KYSE180 cells with or without NELFA mRNA knockdown after IR treatment. As indicated in Fig. 4A, dramatically increased γH2AX immunofluorescence was observed following NELFA mRNA knockdown in the nucleus, which implied that NELFA mRNA knockdown could restrain DNA DSB repair. Similarly, EdU assays demonstrated that NELFA mRNA knockdown significantly inhibited DSB repair (Fig. 4B). Herein, we have to point out that the DNA synthesis of a small...
proportion of cells subjected to IR might not be blocked, their EdU signal might be inevitably included in the results of our EdU assays.

Given that DNA damage repair inhibition might lead to increased cell apoptosis, we next explored the impact of NELFA mRNA knockdown on ESCC cell apoptosis by FCM. As expected, a significantly increased proportion of apoptotic cells was observed in the NELFA mRNA knockdown group after IR (Fig. 4C). Furthermore, the protein level of cleaved caspase-3 was significantly increased after NELFA mRNA knockdown (Fig. 4D). Overall, these results suggest that NELFA mRNA facilitates ESCC cell growth by regulating DNA damage repair and apoptosis.

3.5. NELFA mRNA is required for activation of the DNA damage response

Some studies have established that a proportion of non-coding RNAs participate in the formation of protein complexes. Furthermore, previous studies have revealed that Rad17 interacts with RFC2-5, particularly RFC3/4. Based on these facts, we performed Rad17 co-immunoprecipitation (CoIP) assays to identify whether NELFA mRNA plays an important role in the formation of the Rad17-RFC2-5 complex through RFC3/4. Western blot assays revealed that the interaction between Rad17 and RFC3/4 was inhibited following NELFA mRNA knockdown (Fig. 5A). RFC3/4 CoIP further verified that NELFA mRNA is essential for the formation of the Rad17-RFC2-5 complex (Fig. 5B).

Genomic stability is persistently threatened by genotoxic stress from either internal or environmental sources in eukaryotic cells. To protect the integrity of genomes, cells have developed a series of DNA damage response programmes. Previous findings have indicated that Rad17-RFC2-5 primarily participates in the DNA damage response induced by genotoxic stress and triggers the phosphorylation of ATM/ATR substrates, especially BRCA1, CHK1 and CHK2. Western blot assays revealed that the deletion of NELFA mRNA significantly decreased the phosphorylation of CHK1 and CHK2, which are critical for initiation of the DNA damage repair pathway (Fig. 5C). Furthermore, NELFA mRNA knockdown followed by IR inhibited the phosphorylation of BRCA1, which is mainly responsible for the homologous recombination of DSBs (Fig. 5D). Taken together, the above results
suggest that NELFA mRNA is extensively involved in the DNA damage response pathway by facilitating the formation of the Rad17-RFC2-5 complex.

3.6. NELFA mRNA could be regarded as a prognostic indicator for ESCC

To explore the clinical significance of NELFA mRNA in ESCC, we obtained tissue microarrays including 93 ESCC and 67 para-carcinoma tissues from Outdo Bio-tech Co. Then, RNAscope ISH assays were applied to detect NELFA mRNA expression through the tissue microarrays.

As shown in Fig. 6A, B, NELFA mRNA expression was significantly upregulated in ESCC tissues compared with para-carcinoma tissues. Next, we used Student’s t-test to further analyse the correlation between NELFA mRNA expression and the clinicopathological characteristics of ESCC. As shown in Table 1, the NELFA mRNA-positive rate was correlated with tumour lymph node metastasis (Fig. 6C) and tumour-node-metastasis (TNM) stage (Fig. 6D). Furthermore, we also investigated the relationship between the NELFA mRNA-positive rate and ESCC prognosis. Overall survival analysis using the log-rank test indicated that a higher NELFA mRNA-positive rate was associated with reduced overall survival in ESCC patients (Fig. 6E).

Moreover, to further ascertain the prognostic role of NELFA mRNA expression in ESCC patients, univariate and multivariate Cox regression analyses were conducted. As shown in Table 2, the univariate Cox regression analysis confirmed that the NELFA mRNA-positive rate ($P = 0.010$), gender ($P < 0.001$), lymph node metastasis ($P < 0.001$), T stage ($P = 0.009$) and TNM stage ($P < 0.001$) were vital prognostic factors. The multivariate analysis further revealed that NELFA mRNA expression was an independent prognostic biomarker ($P = 0.047$). Taken together, these results suggest that NELFA mRNA overexpression might be a vital factor in ESCC progression and prognosis.

4. Discussion

Previous studies have shown that lncRNAs play crucial roles in the occurrence and development of ESCC (Wu et al., 2015; Yao et al., 2016; Zhang et al., 2017).
In our study, the most notable finding was that the noncoding function of NELFA mRNA plays an important role in oesophageal cancer progression. We used RIP-Seq assays to identify noncoding RNAs that directly bind to Rad17. Then, RIP-qPCR and RNA pull-down assays were used to verify the interaction between Rad17 and RNAs. Finally, we found that NELFA mRNA interacts with Rad17. Gilot et al. reported that the noncoding function of TYRP1 mRNA facilitated melanoma development (Gilot et al., 2017). Combining the results of previous and current studies, we speculated that the noncoding functions of mRNAs might play an important role in various types of cancer.

Previous studies have reported that Rad17 expression is elevated in colon carcinoma, breast cancer, pancreatic cancer, gastric cancer and non-small-cell lung cancer and is correlated with tumour cell onset and progression (Bao et al., 1999; Fredebohm et al., 2013; Wang et al., 2001). NELFA is an essential element of the NELF complex that negatively regulates the elongation of RNA polymerase II-mediated transcription (Gilchrist et al., 2008; Jadlowsky et al., 2014; Stadelmayer et al., 2014). Previous studies have indicated that NELFA is related to HIV infection and Wolf–Hirschhorn syndrome (Garber and Jones, 1999; Kerzendorfer et al., 2012; Zhang et al., 2007). Until now, very few studies have explored the relationship between NELFA and cancer. In our research, we identified that the expression of NELFA mRNA and Rad17 was higher in ESCC cells than in normal epithelial cells. Moreover, we also revealed that the upregulated transcription factor USF2, at least partly, led to the upregulation of NELFA mRNA and Rad17. USF2, a member of the basic helix–loop–helix leucine zipper transcription factor family, activates transcription through pyrimidine-rich initiator elements and E-box motifs (5-CACGTG-3) and participates in the regulation of multiple cellular...
processes (Belew et al., 2018; Ghosh et al., 1997; Takahashi et al., 2001). Previous studies have shown that USF2 is closely related to ESCC (Xiang et al., 2012). However, the molecular mechanism by which USF2 is involved in ESCC is still unclear. In our study, USF2 exhibited copy number amplification in a variety of cancers according to the TCGA database. RT-qPCR and western blot results also indicated that USF2 was upregulated in ESCC cells. ChIP-qPCR and EMSA demonstrated that USF2 could bind to the promoter regions of Rad17 and NELFA. Moreover, USF2 knockdown led to the reduced expression of Rad17 and NELFA. Taken together, these results indicate that the molecular mechanism by which USF2 is involved in ESCC onset and progression might partially be explained by the increased expression of Rad17 and NELFA.

Our results provide novel insight into the important role of NELFA in the onset and progression of ESCC through a noncoding function. Given that previous studies have suggested that Rad17 is mainly located in and functions in the cell nucleus (Post et al., 2003), we first investigated the distribution of NELFA mRNA in cells. By separating the nuclear and cytoplasmic fractions, we found that NELFA mRNA was expressed in both the cytoplasm and nucleus. Subsequently, to explore the function of NELFA mRNA, we designed two different ASOs to specifically silence NELFA mRNA in the cell nucleus with no impact on the protein expression level.

Antisense oligonucleotides are short oligonucleotides that localize to the nucleus and provide a pathway for gene silencing by the RNase H pathway. As we all know, RNase H, specifically located in the nucleus, could degrade all the RNAs in DNA and RNA double heterozygous strands. Furthermore, in ASO knockdown group, the NELFA mRNA expression level decreased by a certain percentage, which was comparably equivalent with the proportion of NELFA mRNA distributed in the nucleus. In view of this, we silenced NELFA mRNA expression in the nucleus with no impact on the protein expression level in our experiment. Besides, ASO2 and ASO3 were designed to respectively combine with the exon 8 and exon 11 of NELFA mRNA. NELFA mRNA knockdown inhibited ESCC cell proliferation and clone formation ability. In addition, silencing NELFA mRNA in the cell

Fig. 6. NELFA mRNA can be used as a biomarker for ESCC prognosis. (A, B) RNAscope ISH assays were used to detect NELFA mRNA expression in the tissue microarray. The red arrow indicates the NELFA mRNA signalling point. Normal n = 67, tumour n = 93. (C) The correlation between the NELFA mRNA-positive rate and lymph node metastasis. N0 n = 43, N1–3 n = 48. (D) The correlation between the NELFA mRNA-positive rate and TNM stage. Stage I + II n = 44, stage III n = 44. (E) Kaplan–Meier survival analysis of ESCC patients’ overall survival based on the NELFA mRNA-positive rate in the tissue microarray. Low expression n = 46, high expression n = 47. Scale bar = 50μm.*P < 0.05, **P < 0.01 and ***P < 0.001. Significance was determined by Student’s t-test.
nucleus also suppressed DNA damage repair and facilitated ESCC cell apoptosis. This result implies that NELFA mRNA regulates ESCC cell growth, at least partially, through its regulation of DNA damage-associated apoptosis. Considering that NELFA mRNA overexpression or knockout would inevitably influence the expression of NELFA protein, we did not perform these assays in ESCC cells.

Many studies have suggested that noncoding RNAs participate in the formation of protein complexes (McHugh et al., 2015; Munschauer et al., 2018; Wen et al., 2018). Previous results have suggested that Rad17 interacts with RFC2-5 (Majka and Burgers, 2004). The interaction between Rad17 and RFC2-5 is involved in ATM- and/or ATR-mediated substrate phosphorylation through a complicated regulatory network (Foray et al., 2003; Shiotani et al., 2013; Zou et al., 2002). Our data indicated that NELFA mRNA knockdown inhibited the interaction between Rad17 and RFC3/4. We also found that NELFA mRNA knockdown inhibited the phosphorylation of CHK1, CHK2 and BRCA1, which would have an impact on the DNA damage repair pathway. In conclusion, NELFA mRNA promotes ESCC initiation and progression by facilitating the formation of the Rad17-RFC2-5 complex. However, the underlying mechanism of the ATM- and/or ATR-mediated DNA damage repair signalling pathway regulated by Rad17 and NELFA mRNA needs further exploration.

Oesophageal cancer is one of the deadliest cancers, with a 5-year survival rate of ~20% (Li et al., 2018). In our study, we used RNAscope ISH assays to detect NELFA mRNA expression in an ESCC tissue microarray. NELFA mRNA was significantly upregulated in ESCC tissues compared with para-carcinoma tissues ($P < 0.001$). In addition, the NELFA mRNA expression level was positively correlated with tumour lymph node metastasis ($P < 0.05$) and TNM stage ($P < 0.01$). The overall survival analysis indicated that high NELFA mRNA expression was associated with reduced overall survival in ESCC patients. Moreover, univariate and multivariate Cox regression analyses further revealed that NELFA mRNA expression was an independent prognostic biomarker ($P = 0.047$). These results suggest that NELFA mRNA expression can be regarded as a biomarker for ESCC prognosis.

### 5. Conclusions

In summary, our results demonstrated that NELFA mRNA could interact with Rad17 in a noncoding mode and promote ESCC cell growth, at least partially, by

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|----------------------|
|          | HR (95% CI)         | $P$ value            | HR (95% CI) | $P$ value |
| NELFA mRNA-positive rate | 1.83 (1.159–2.898) | 0.010                | 1.602 (1.007–2.550) | 0.047 |
| Age (< 66 years vs. ≥ 66 years) | 0.909 (0.579–1.429) | 0.680                |              |          |
| Gender (male vs. female) | 2.684 (1.180–3.682) | 0.011                |              |          |
| N (N = 0 vs. N = 1–3) | 2.325 (1.452–3.724) | < 0.001              |              |          |
| T (T = 1–2 vs. T = 3–4) | 2.061 (1.193–3.558) | 0.009                |              |          |
| Stage (I + II vs. III) | 2.602 (1.678–4.035) | < 0.001              | 2.408 (1.556–3.727) | < 0.001 |

$^a$Statistical significant results (in bold).
facilitating DNA damage repair. In addition, upregulated NELFA mRNA was related to cancer progression and a poor prognosis. These results suggest a strategy for targeting NELFA mRNA as a therapeutic target for ESCC in the future.

Acknowledgements
This work is supported by the National Basic Research Program of China (973 Program) (2015CB553904) and National Natural Science Foundation of China (81490753 and 81830086). The result of USF2 copy number variation is based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. This work is supported by the National Basic Research Program of China (973 Program) (2015CB553904) and National Natural Science Foundation of China (81490753 and 81830086).

Conflict of interest
The authors declare no conflict of interest.

Data accessibility
Cistrome DB (http://cistrome.org/db/#/)
ENCODE (https://www.encodeproject.org/)
GEPIA (http://gepia.cancer-pku.cn/)
RPISeq (http://pridb.gdcb.iastate.edu/RPISeq/)
TCGA (https://www.cancer.gov/)

Author contributions
QZ contributed to conceptualization, administered project, supervised the study and acquired funding. JX contributed to methodology; wrote, reviewed and edited the manuscript; curated the data; and developed the software. GW performed formal analysis and curated the data. WG contributed to visualization and curated the data. SG validated the study. DL participated in investigation.

Ethics approval and consent to participate
Our research was approved by the Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.

References
Alsop BR and Sharma P (2016) Esophageal cancer. *Gastroenterol Clin North Am* **45**, 399–412.

Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, Zhang J, Liu Y, Qian X, Sutherland R *et al.* (1999) HRad17, a human homologue of the *Schizosaccharomyces pombe* checkpoint gene rad17, is overexpressed in colon carcinoma. *Can Res* **59**, 2023–2028.

Bao S, Shen X, Shen K, Liu Y and Wang XF (1998) The mammalian Rad24 homologous to yeast *Saccharomyces cerevisiae* Rad24 and *Schizosaccharomyces pombe* Rad17 is involved in DNA damage checkpoint. *Cell Growth Differ* **9**, 961–967.

Bao S, Tibbetts RS, Brumbaugh KM, Fang Y, Richardson DA, Ali A, Chen SM, Abraham RT and Wang XF (2001) ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. *Nature* **411**, 969–974.

Bastide MF, Bido S, Duteil N and Bezzard E (2016) Striatal NELF-mediated RNA polymerase II stalling controls L-dopa induced dyskinesia. *Neurobiol Dis* **85**, 93–98.

Belew MS, Bhatia S, Keyhani Chahi A, Rentas S, Draper JS and Hope KJ (2018) PLAG1 and USF2 co-regulate expression of Musashi-2 in human hematopoietic stem and progenitor cells. *Stem Cell Reports* **10**, 1384–1397.

Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J and Sancar A (2003) Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. *Proc Natl Acad Sci USA* **100**, 1633–1638.

Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, Hilton JA, Jain K, Baymuradov UK, Narayanan AK *et al.* (2018) The encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic Acids Res* **46**, D794–D801.

Domper Arnal MJ, Ferrandez Arenas A and Lanas Arbeloa A (2015) Esophageal cancer: Risk factors, screening and endoscopic treatment in western and eastern countries. *World J Gastroenterol* **21**, 7933–7943.

Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M, Ashworth A and Jeggo P (2003) A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. *EMBO J* **22**, 2860–2871.

Fredebohm J, Wolf J, Hoheisel JD and Boettcher M (2013) Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. *J Cell Sci* **126**, 3380–3389.

Garber ME and Jones KA (1999) HIV-1 Tat: coping with negative elongation factors. *Curr Opin Immunol* **11**, 460–465.

Ghosh AK, Datta PK and Jacob ST (1997) The dual role of helix-loop–helix-zipper protein USF in ribosomal RNA gene transcription *in vivo*. *Oncogene* **14**, 589–594.

Gilchrist DA, Nechaev S, Lee C, Ghosh SK, Collins JB, Li L, Gilmour DS and Adelman K (2008) NELF-mediated stalling of Pol II can enhance gene expression
by blocking promoter-proximal nucleosome assembly. *Genes Dev* **22**, 1921–1933.

Gilot D, Migault M, Bachelot L, Journe F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B et al. (2017) A non-coding function of TYRP1 mRNA promotes melanoma growth. *Nat Cell Biol* **19**, 1348–1357.

Griffith JD, Lindsey-Boltz LA and Sancar A (2002) Structures of the human Rad17-replication factor C and checkpoint Rad 9-1-1 complexes visualized by glycerol spray/low voltage microscopy. *J Biol Chem* **277**, 15233–15236.

Hirai I and Wang HG (2002) A role of the C-terminal region of human Rad9 (hRad9) in nuclear transport of the hRad9 checkpoint complex. *J Biol Chem* **277**, 25722–25727.

Huang FL and Yu SJ (2018) Esophageal cancer: risk factors, genetic association, and treatment. *Asian J Surg* **41**, 210–215.

Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K and Karn J (2014) Negative elongation factor is required for the maintenance of provaline latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. *Mol Cell Biol* **34**, 1911–1928.

Kerzendorfer C, Hannes F, Colnaghi R, Abramowicz I, Kerzendorfer C, Hannes F, Colnaghi R, Abramowicz I, Huang FL and Yu SJ (2018) Esophageal cancer: risk factors, genetic association, and treatment. *Asian J Surg* **41**, 210–215.

Li Y, Hofheinz F, Furth C, Lili C, Hua W, Ghadjar P and Zschaecck S (2018) Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. *Eur J Nucl Med Mol Imaging* **45**, 1752–1761.

Lindsey-Boltz LA, Bermudez VP, Hurwitz J and Sancar A (2001) Purification and characterization of human DNA damage checkpoint Rad complexes. *Proc Natl Acad Sci USA* **98**, 11236–11241.

Majka J and Burgers PM (2004) The PCNA-RFC families of DNA clamps and clamp loaders. *Prog Nucleic Acid Res Mol Biol* **78**, 227–260.

Masuiki Y, Tanaka T, Makino T, Yamasaki M, Miyaizaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mori M and Doki Y (2018) Esophageal squamous cell carcinoma with low mitochondrial copy number has mesenchymal and stem-like characteristics, and contributes to poor prognosis. *PLoS ONE* **13**, e0193159.

McHugh CA, Chen CK, Chow A, Surka CF, Tran C, McDonel P, Pandya-Jones A, Blanco M, Burghard C, Moradian A et al. (2015) The Xist IncRNA interacts directly with SHARP to silence transcription through HDAC3. *Nature* **521**, 232–236.

Medhurst AL, Warmerdam DO, Akerman I, Verwayen EH, Kanar A, Smits VA and Lakin ND (2008) ATR and Rad17 collaborate in modulating Rad9 localization at sites of DNA damage. *Cell Sci* **121**, 3933–3940.

Munschauer M, Nguyen CT, Sirokman K, Hartigan CR, Hogstrom L, Engreitz JM, Ulirsch JC, Fulco CP, Subramanian V, Chen J et al. (2018) The NORAD IncRNA assembles a topoisomerase complex critical for genome stability. *Nature* **561**, 132–136.

Muppirala UK, Honavar VG and Dobbs D (2011) Predicting RNA-protein interactions using only sequence information. *BMC Bioinformatics* **12**, 489.

Natarajan M, Schiralli Lester GM, Lee C, Missra A, Wasserman GA, Steffen M, Gilmore DS and Henderson AJ (2013) Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription. *J Biol Chem* **288**, 25995–26003.

Pagano JN, Kwak H, Waters CT, Sprouse RO, White BS, Ozer A, Sztok K, Shalloway D, Craighead HG and Lis JT (2014) Defining NELF-E RNA binding in HIV-1 and promoter-proximal pause regions. *PLoS Genet* **10**, e1004090.

Ping YH and Rana TM (2001) DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. *J Biol Chem* **276**, 12951–12958.

Post SM, Tomkinson AE and Lee EY (2003) The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. *Nucleic Acids Res* **31**, 5568–5575.

Sasaki H, Chen LB, Auclair D, Moriyama S, Kaji M, Fukui I, Kiriyma M, Yamakawa Y and Fujii Y (2001) Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis. *Lung Cancer* **34**, 47–52.

Shiotani B, Nguyen HD, Hakansson P, Marechal A, Tse A, Tahara H and Zou L (2013) Two distinct modes of ATR activation orchestrated by Rad17 and Nbs1. *Cell Rep* **3**, 1651–1662.

Stadelmayer B, Micas G, Gamot A, Martin P, Malirat N, Koval S, Raffel R, Sobhian B, Severac D, Rialle S et al. (2014) Integrator complex regulates NELF-mediated RNA polymerase II pause/release and processivity at coding genes. *Nat Commun* **5**, 5531.

Takahashi K, Nishiyama C, Nishiyama M, Okumura K, Ra C, Ohtake Y and Yokota T (2001) A complex composed of USF1 and USF2 activates the human FcsipsonRI alpha chain expression via a CAGCTG element in the first intron. *Eur J Immunol* **31**, 590–599.
Takeishi Y, Iwaya-Omi R, Ohashi E and Tsurimoto T (2015) Intramolecular binding of the Rad9 C terminus in the checkpoint clamp Rad9-Hus1-Rad1 is closely linked with its DNA binding. *J Biol Chem* **290**, 19923–19932.

Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* **45**, W98–W102.

Wang X, Wang L, Callister MD, Putnam JB, Mao L and Li L (2001) Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. *Can Res* **61**, 7417–7421.

Wen X, Liu X, Mao YP, Yang XJ, Wang YQ, Zhang PP, Lei Y, Hong XH, He QM, Ma J *et al.* (2018) Long non-coding RNA DANCR stabilizes HIF-1alpha and promotes metastasis by interacting with NF90/NF45 complex in nasopharyngeal carcinoma. *Theranostics* **8**, 5676–5689.

Wu H, Zheng J, Deng J, Zhang L, Li N, Li W, Li F, Lu J and Zhou Y (2015) LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis. *Oncogene* **34**, 4723–4734.

Xiang J, Zang W, Che J, Chen K and Hang J (2012) Regulation network analysis in the esophageal squamous cell carcinoma. *Eur Rev Med Pharmacol Sci* **16**, 2051–2056.

Yao W, Bai Y, Li Y, Guo L, Zeng P, Wang Y, Qi B, Liu S, Qin X, Li Y *et al.* (2016) Upregulation of MALAT-1 and its association with survival rate and the effect on cell cycle and migration in patients with esophageal squamous cell carcinoma. *Tumour Biol* **37**, 4305–4312.

Yoshimizu S, Yoshio T, Ishiyama A, Tsuchida T, Horiuchi Y, Omae M, Hirasawa T, Asari T, Chin K and Fujisaki J (2018) Long-term outcomes of combined endoscopic resection and chemoradiotherapy for esophageal squamous cell carcinoma with submucosal invasion. *Dig Liver Dis* **50**, 833–838.

Zhang E, Han L, Yin D, He X, Hong L, Si X, Qiu M, Xu T, De W, Xu L *et al.* (2017) H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. *Nucleic Acids Res* **45**, 3086–3101.

Zhang Z, Klatt A, Gilmour DS and Henderson AJ (2007) Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. *J Biol Chem* **282**, 16981–16988.

Zhou Z, Jing C, Zhang L, Takeo F, Kim H, Huang Y, Liu Z and Wan Y (2013) Regulation of Rad17 protein turnover unveils an impact of Rad17-APC cascade in breast carcinogenesis and treatment. *J Biol Chem* **288**, 18134–18145.

Zou L, Cortez D and Elledge SJ (2002) Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. *Genes Dev* **16**, 198–208.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Transcription factor analysis of Rad17 and NELFA in database.

Table S1. The list of primers.

Table S2. Information of antibodies.

Table S3. siRNAs, ASOs and EMSA probe sequence.